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Abstract Stanniocalcin 2 (STC2) is a novel member of
the Stanniocalcin family, the function of which remains
unclear. Its expression is clinically significant in several
cancers. The aim of this study was to evaluate the clinical
value of measuring expression levels of STC2 in colo-
rectal cancer (CRC) patients. A total of 47 tumor and
matched tumor-free margin samples were obtained during
surgery. The STC2 mRNA expression level in tumor and
marginal tissue was examined by real-time quantitative
PCR. STC2 mRNA expression levels were higher in
tumor tissues than the control. (r = 0.36, p B 0.02).
mRNA expression level of STC2 was significantly
associated with tumor size (p B 0.05) and histologic
grade (p B 0.05). Our study demonstrated that STC2 was
significantly expressed in CRC patients, relative to the
control. STC2 can therefore be used as a biomarker to
differentiate between tumor borders and margins. Ana-
lysis of STC2 gene expression during surgery could be
useful in reducing surgical error in tumor removal and
increasing overall success of surgery with improved
tumor clearance. However, in some cases such as where
the tumor is end-stage, the expression of such a biomarker
may not be clinically beneficial to record. The consider-
ation of marginal samples as a control group can help
reduce the effect of confounding factors such as racial
and individual differences.
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Introduction
Colorectal cancer (CRC) is the second leading cause of
cancer-related deaths in the USA [1]. It is also the leading
cause of death in the Western world [2]. With approximately
51,000 cases of diagnosed CRC per year and 35,000 deaths,
Iran boasts the second highest cancer death rate in the East-
Mediterranean region [3, 4]. In Asia, the overall cure rate of
CRC has not improved dramatically in the last decade, with a
5-year survival remaining at approximately 60 %. CRC
survival time has increased in recent years, but the mortality
rate remains high [5]. To improve the cure rates for patients
with CRC, the primary tumors must be detected at an early
stage and recurrent disease must be diagnosed while it is still
minimal or clinically occult. Micro-metastases are currently
undetectable by conventional methods [6, 7]. Conventional
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serum markers, however, lack sufficient sensitivity and
specificity to facilitate early detection. To improve the poor
survival outcome and to permit earlier diagnosis, there is a
need for more sensitive biomarkers than those currently
available.
Stanniocalcin (STC) is a glycoprotein hormone which is
produced in the corpuscles of Stannius. Involved in cal-
cium and phosphate homeostasis in fish, this organ is yet to
be found in higher vertebrates [8, 9]. STC1 has been
identified in mammals by sequence homology. However,
its functions have still not been completely identified, even
though the human sequence can be functionally active in
fish, implicating a similar mode of action [10]. STC2 is a
novel member of the family and was identified by sequence
homology to STC1 (30 % identity and 60 % homology) in
an EST database [11, 12]. The secreted protein consists of
302 amino acids and possesses a cysteine-rich N-terminal
region suggesting homodimerization, as well as potential
phosphorylation and glycosylation sites. In adult human
tissue, high STC2 transcript levels have been found in the
heart, pancreas, testis and muscle, whereas in embryonic
tissues, kidneys and lungs have revealed high expression
levels [11, 13]. However, its exact functions remain
unclear. Unlike STC1, for which a receptor is likely to exist
[14], receptors for STC2 have not been detected so far,
making functional classification even more difficult. STC2
may play a role in the regulation of renal and intestinal
calcium and phosphate transport, cellular homeostasis and
glucose metabolism [15, 16]. The inverse regulation pat-
terns of STC1 and STC2 have led to the assumption that
STC2 may act as a counter-regulator to STC1 [17].
In several cancer cell lines, STC2 was found to be up-
regulated [17, 18]. Functional studies have not been carried
out yet to reveal the impact of STC2 in cancer. The
expression of STC2 is clinically significant in several
cancers, including renal cell carcinoma [19], prostate
cancer [20], colorectal cancer [21], neuroblastoma [22],
esophageal squamous cell cancer [23] and gastric cancer
[24, 25].
It is clear that STC2 overexpression in cancer tissues is
associated with carcinoma development and poor progno-
sis. On the other hand, STC2 expression is also upregulated
in estrogen receptor (ER)-positive breast cancer patients;
however, the prognoses for these cases are good. The
clinical significance of STC2 in cancer is controversial and
depends on the cancer type [26–28].
In this study, we examined the expression levels of
STC2 in CRC samples to evaluate whether the expression
level of STC2 in cancer tissues can be used as a prognostic
tool in CRC patients. Moreover, we performed this study to
determine whether STC2 might be a helpful biomarker to
differentiate the border of the tumor with the margin during
surgery.
Materials and methods
Study design
A cross-sectional study was carried out under collaboration
between the Imam Reza Hospital and Tabriz Genetic
Analysis Center of Tabriz University of Medical Sciences.
The protocol of the study was approved by the Ethical
Committee of Tabriz University of Medical Sciences
(TUMS), which was in compliance with the Helsinki
declaration. Written informed consent was obtained from
all participants.
Study population
A total of 47 tumor and matched tumor-free margin sam-
ples were obtained during surgery. All patients underwent
appropriate surgery at Imam Reza Hospital of Tabriz and
affiliated hospitals between 2010 and 2013. All patients
were clearly identified as having CRC based on the clini-
copathological findings. All of the samples were referred to
the Tabriz Genetic Analysis Center (TGAC) with infor-
mation including patients demographic and clinicopatho-
logical data.
The median age of patients with CRC was
55.25 ± 13.47 years (range 23–76 years), and the samples
comprised of 22 (46.8 %) males and 25 (53.2 %) females.
None of the patients had received preoperative chemo-
therapy and/or radiotherapy and have no other malignan-
cies. Pathologically identified, samples were separated into
two groups including 47 tumor and 47 marginal sample
controls.
Sample preparation
All samples were obtained immediately after surgery,
incubated overnight at 4 C in RNAlater (Qiagen, Ger-
many) and were subjected to total RNA extraction using
RNeasyTMmini kit (Qiagen) as recommended by the
manufacturer. RNA concentration was then measured and
3 ll of RNA was treated with 1 ll of DNAase, 1 ll of
buffer and 5 ll of water and incubated at 37 C for 30 min.
One microliter of EDTA was then added and incubated at
65 C. A cDNA library was then constructed using RT-
PCR. cDNA was synthesized from 2 lg of total RNA using
a random hexamer primer and reverse transcriptase.
Specific RT-PCR
PCR primer pairs were designed for mRNA sequencing of
each gene (Table 1). Specific RT-PCR for ß-actin and
STC2 genes was carried out with all samples. Briefly, for
each sample, 2 ll of cDNA was added to 5 ll of red master
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mix (Ampliqon, Denmark) and 2 ll of ß-actin forward and
reverse primers with 1 ll water then placed in a thermal
cycler (Eppendrof, Germany) with the following setting:
4 min at 95 C, followed by 35 cycles of 94 C for 30 s,
59 C for 30 s, 72 C for 1 min and finally, followed by 1
cycle at 72 C for 5 min. PCR products were then run on
1.5 % agarose gel with band sizes of STC2 and ß-actin
genes at 254 and 289 bp, respectively.
Standards as gene-specific quantity marker
A dilution series of human genomic standards for calibra-
tion of real-time PCR was generated using human genomic
DNA (hgDNA). hgDNA (Promega, USA) was homoge-
nized by sonication and serially diluted in Tris–EDTA (TE)
buffer to produce standards in which the number of DNA
molecules ranged from 1/10 to 1/100,000. Each standard
was then placed into aliquots of 1 ml and stored at -20 C.
Real-time quantitative PCR
Primers for SYBR Green real-time PCR were designed for
each gene using Primer Express Software (Perkin Elmer/
Applied Biosystems, USA), details of which are shown in
Table 1. For each gene, SYBR Green real-time PCR was
performed in 25 ll target volume using 5 ll of cDNA from
each sample, 12.5 ll SYBR Green master mix and 3.75 ll
of each gene-specific forward and reverse primers. All real-
time PCRs were performed with the following settings:
5 min at 95 C, followed by 40 cycles of 95 C for 15 s,
60 C for 20 sand 72 C for 40 s. All samples, as well as
the five serial human genomic standards, were measured in
each gene. Negative controls (NTC) were prepared each
time. Samples were analyzed using an ABI Prism sequence
detection system, (PE Applied Biosystems, USA) as rec-
ommended by the manufacturer.
Normalization
Normalization using the housekeeping gene b-actin was
used in order to identify the expression levels of the STC2
gene. The expression levels of the housekeeping gene (ß-
actin) and the STC2 genes were measured by real-time
PCR. The mean cycle threshold (Ct) values and the copy
number of each gene were determined by reference. The
mean copy number of the housekeeping gene was calcu-
lated and then divided by the highest housekeeping gene in
all samples, resulting in a normalization correction factor.
Following real-time PCR amplification and quantification
of the selected genes, this factor was used for the nor-
malization of the expression levels for the STC2 genes
measured. The standard curves, which were plotted, dem-
onstrated the ability of the method to accurately measure
the expression levels of the STC2 gene.
Statistical analysis
Initial analysis indicated that the data were not normally
distributed; therefore, nonparametric tests were used.
Spearman correlation coefficient was used. Also, statistical
analysis was performed in each of the diagnostic groups
using Mann–Whitney U and Kruskal–Wallis with p \ 0.05
deemed as statistically significant. All tests were performed
using SPSS (version 22).
Results
Gene-specific PCR
To investigate the expression pattern and quantification of
the STC2 gene, all samples were separated into two
groups: tumor and margin. After RNA extraction, a cDNA
library was constructed from each sample. To confirm that
the PolyA cDNA produced from all of the samples can be
used to detect the STC2 gene expression in real-time
PCR, specific RT-PCR was performed for ß-actin and
STC2 genes. ß-actin PCR was positive in all of the
samples, and bands of appropriate sizes were present in
all of the samples (Fig. 1), demonstrating the presence of
the target transcript in the polyA cDNA (cDNA Quality
Confirmation). STC2 PCR was negative in some samples
(Fig. 1).
Real-time quantitative PCR
For each gene, real-time PCR was applied in an ABI step one
system. Negative template controls (NTC) and human
genomic standards were prepared each time. Standard
curves were plotted using Ct values of the fivefold serial
dilutions of the human genomic DNA for the optimization
and efficiency of real-time PCR reactions. The efficiency of
the real-time PCR reactions was calculated from the slope of
the standard curve. A representative example of a real-time
PCR amplification plot and standard curve of the STC2 gene
is shown in Fig. 2. Real-time PCR amplifications were
performed using STC2-specific primers and probes. The
Table 1 Primers used for PCR
AATGGATCATCTCCACTATCACC STC2: Reverse
CTTACATGGGATTTGCATGACTT STC2: Forward
CGGAACCGCTCATTGCC ß-actin: Reverse
ACCCACACTGTGCCCATCTA ß-actin: Forward
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standard curve shows amplification efficiencies of fivefold
serial dilutions of the human genomic DNA (Fig. 2).
Expression of STC2 mRNA in tumor and marginal
sample tissues
STC2 mRNA expression level in tumor and marginal
tissues of CRC patients was examined by real-time
quantitative PCR. Using spearmen correlation coefficient,
results indicated that STC2 mRNA expression levels were
higher in tumor tissues than marginal groups as a control
group (r = 0.36, p B 0.02). The median expression level
in tumor groups was 31,829 and the minimum and max-
imum level were 2,366 and 25,183,989. The median
expression levels in marginal groups were 7,303.5 and the
minimum and maximum level were 681 and 1,296,806,
respectively.
In order to assess the expression pattern and quantifi-
cation of the STC2 gene in tumor and marginal samples,
comparison of the STC2 gene expression was performed in
tumor and margin samples. Distribution of the expression
levels of STC2 gene in the tumor and marginal samples
indicated that the over-expression of STC2 in tumor sam-
ples is higher (83 %) than tumor-free marginal samples
(17 %). On the other hand, in the majority of samples, the
expression level of STC2 in marginal tumor-free tissue is
lower than real tumor samples [For example in patients no
26 (Fig. 3)]. The variance of expression is high in all, but
the one sample of patient number 17 where expression
levels are similar (Fig. 4)
Expression level of STC2 in tumor tissues
and clinicopathological factors
Clinicopathological factors were analyzed in relation to
STC2 expression status (Table 2).
As data were not normally distributed, spearman cor-
relation coefficient was used. mRNA expression level of
STC2 was significantly associated with the size (p B 0.05)
and histologic grade of tumors (p B 0.05) in Mann–whit-
ney U and Kruskal–Wallis tests (Table 2).
Discussion
We performed real-time RT-PCR for STC2 transcripts on
47 tumor and tumor-free margin tissue samples. We found
that the expression level of STC2 in CRC is high compared
with normal tissue (p B 0.05). There was significant
association between tumor size and the histological grade
of the tumors and over-expression of STC2 in tumor tis-
sues. Regarding the expression levels of STC2 in tumor
and tumor-free margin samples, we also showed that STC2
can be as a biomarker to differentiate between tumor bor-
ders and margins during surgery.
While the precise physiological function of STC2 has
not been clearly identified [29], one of the important
characteristics of STC2 is that its contribution to carcinoma
development depends on cancer type. Our study on CRC
patients indicated that STC2 was over-expressed in can-
cerous tissue. This result is consistent with a study which
showed that the expression of STC2 is clinically significant
in gastric cancer [24, 25], prostate cancer [20], renal cell
carcinoma [19], neuroblastoma [22] and esophageal squa-
mous cell cancer [23]. However, STC2 over-expression in
breast cancer is associated with good prognoses, particu-
larly ER-positive breast cancers [26–28]. ER-positive
breast cancers are usually low-grade malignancies and are
effectively treated with hormonal therapies, unlike HER2
and triple-negative types, which may be the basis of the
good prognosis [30, 31]. STC2 (-/-) mice are 10–15 %
larger and grow at a faster rate than wild-type mice;
Beta-actin
Beta-actin
STC2
STC2
M T M T M T M T M T M T MFig. 1 ß-actin and STC2
expression in some of the
samples of CRC. Ma Marker,
T Tumor, M Margin
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however, the growth of transgenic mice over-expressing
human STC2 is inhibited [32, 33].
Therefore, it has been suggested that the function of STC2
is related to the inhibition of cellular proliferation. In
microarray studies, it was reported that expression of STC1
increased tenfold in tumors compared with normal mucosa in
CRC [34] and STC2 is one of the over-expression genes in
CRC cells [35]. Ieta et al. [21] have found that STC2 gene
expression was higher in 89.2 % of CRC cases. In addition,
tumors with high STC2 expression showed higher frequen-
cies of lymph node metastasis, lymphatic invasion, tumor
depth, tumor size and AJCC stage classification. In our study,
high mRNA expression level of STC2 was associated with
tumor size and the histological grade of the tumor. These
findings showed the importance of the STC2 gene in the
clinicopathological manifestations of patients with CRC.
This study is the first study which simultaneously
evaluated the expression level of the STC2 gene in tumor
and marginal normal tissues in cancer patients. Marginal
samples were considered as control group which can help
reduce the effect of confounding factors such as race,
geographical and individual differences. All previous
studies investigating STC2 expression in various cancers
were in vitro, with some comparing tumor tissue of patient
with normal tissue from other patients. These studies were
therefore prone to confounding factors which were con-
trolled for in our investigation.
It was suggested that a quick analysis of STC2 gene
expression during surgery could be useful in reducing
surgical error in tumor removal, tumor clearance, non-
recurring and the success of surgery. However, in some
cases such as end-stage cancer, the evaluation of the
expression of the STC2 gene may be less helpful. In CRC,
there is an interval of about 25 years between formation of
colon adenomas and the symptoms of the disease [36].
Therefore, such molecular studies and early screening
could replace the old routine of histopathological diagno-
sis. Microarray analysis has been used for screening of
CRC in many recent studies [36–38]. Unfortunately, due toFig. 2 Real-time PCR quantification of STC2 mRNA
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Fig. 3 Comparison of the
expression level of STC2 in
tumor and marginal samples
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the cost, time period required and complexity of the tech-
nique, it is not a useful routine laboratory diagnosis tech-
nique. Because of this, measuring the expression level of
selected genes such as STC2 as a form of routine molecular
testing is necessary. It seems that STC2 is a helpful
molecular biomarker in the CRC diagnosis. In conclusion,
STC2 may be a promising candidate for the targeted
treatment of CRC. Other parallel studies are needed to
decipher the precise mechanism of action of the STC2 gene
in carcinogenicity.
Fig. 4 Expression level of STC2 in marginal samples
Table 2 STC2 gene expression
and clinicopathological factors
in 47 CRC patients
Ma Marker, T Tumor, M Margin
a Median expression level
 Well, well differentiated;
poor, poorly differentiated;
moderate, moderately
differentiated
Clinicopathologic variable Mediana Min Max p value
Age 0.65
\50 28,674 2,366 25,183,989
[50 32,450 5,851 342,158
Gender 0.39
Male 30,010 5,851 25,183,989
Female 42,926 2,366 680,419
Tumor size 0.04
\3 319,454 108,471 680,419
C3 30,382 2,366 25,183,989
Histology 0.03
Well 35,821 2,366 13,299,190
Moderate 19,856 3,104 25,183,989
Poor 191,345 42,926 921,105
Depth 0.36
T2, T3 47,441 4,243 680,419
T4 30,028 2,366 25,183,989
Lymph node metastasis 0.63
Absent 41,252 4,243 680,419
Present 30,364 2,366 25,183,989
Venous invasion 0.47
Absent 33,330 4,243 680,419
Present 30,382 2,366 25,183,989
AJCC stage classification 0.96
I, II 34,873 4,243 680,419
III, IV 31,303 2,366 25,183,989
Liver metastasis 0.1
Absent 30,382 2,366 25,183,989
Present 71,497 3,002 813,299,190
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